Moderna, Inc. Common Stock (MRNA) Financial Statements
Historical financial data — 31 statements covering FY2018–FY2025
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was author...
Moderna, Inc. Common Stock's revenue decreased 39.9% year over year, from $3.24B to $1.94B.
Net income increased 20.8% over the same period, from $-3.56B to $-2.82B.
Over the 7-year period from FY2018 to FY2025, revenue grew by 1339% in total.
The debt-to-equity ratio stands at 0.07, indicating a conservative leverage profile.
Operating cash flow grew 37.6% to $-1.87B.
Moderna, Inc. Common Stock maintains a negative net profit margin of -145.2%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $1.86B+672.6% | $13.0M | $1.35B | $-70.0M | $-1.57B | $15.80B | N/A | $11.93B |
| Q4 FY2024 | $966.0M-48.1% | $-1.12B | $227.0M | $-1.25B | $825.0M | $14.14B | N/A | $10.90B |
| Q1 FY2025 | $108.0M-88.8% | $-971.0M | $18.0M | $-1.05B | $-1.04B | $12.70B | N/A | $10.07B |
| Q2 FY2025 | $142.0M+31.5% | $-825.0M | $23.0M | $-907.0M | $-919.0M | $12.01B | N/A | $9.40B |
| Q3 FY2025 | $1.02B+615.5% | $-200.0M | $809.0M | $-260.0M | $-847.0M | $12.13B | N/A | $9.33B |
| Q4 FY2025 | $678.0M-33.3% | $-826.0M | $226.0M | $-857.0M | $930.0M | $12.34B | $590.0M | $8.65B |
| Q1 FY2026 | $389.0M-42.6% | $-1.34B | $-566.0M | $-510.0M | $-630.0M | N/A | N/A | N/A |
| Q2 FY2026 | $145.0M-62.7% | $-782.0M | $52.0M | $-809.0M | $-526.0M | N/A | N/A | N/A |
Balance Sheet Summary (FY2025)
Moderna, Inc. Common Stock (MRNA) Financial Statements & Revenue History
Moderna, Inc. Common Stock (MRNA) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry trading at $215.69 with a market capitalization of $86. This page provides 31 historical financial statements for Moderna, Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Moderna, Inc. Common Stock reported revenue of $1.9 billion, a 39.9% decline from the prior year. The net profit margin of -145.2% indicates the company is currently unprofitable. The debt-to-equity ratio of 0.07 shows conservative leverage.
MRNA Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Moderna, Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether MRNA is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track MRNA's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Moderna, Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of MRNA's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use MRNA Financial Data
Investors use Moderna, Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare MRNA's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how MRNA's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View MRNA's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Moderna, Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.MRNA trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.